Strategic partnerships Opportunity to re-engage or establish new collaborations for AMITIZA or related GI therapies with regional players given past partnerships with Takeda and Dr. Reddy’s, focusing on markets where Takeda no longer markets AMITIZA.

Global footprint Leverage Sucampo's international presence in Japan, Switzerland, the U.K., and the U.S. to target multinational distributors and contract manufacturers interested in rare disease and unmet medical needs, expanding access through global channels.

Portfolio focus AMITIZA and RESCULA offer established revenue streams; identify opportunities with specialty wholesalers and patient support programs to optimize uptake, adherence, and payer coverage in targeted GI and ophthalmology segments.

Financial leverage With a mid-market revenue band and substantial funding, pursue partnerships for co-development or commercialization rights, leveraging capital for late-stage trials, market expansion, or licensing deals in high-potential geographies.

M&A and diligence Historical activity around acquisitions and licensing suggests openness to strategic transactions; position Sucampo as a potential bolt-on target or partner for companies seeking to augment rare disease portfolios or global commercialization capabilities.